CA2472186A1 - Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein - Google Patents

Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein Download PDF

Info

Publication number
CA2472186A1
CA2472186A1 CA002472186A CA2472186A CA2472186A1 CA 2472186 A1 CA2472186 A1 CA 2472186A1 CA 002472186 A CA002472186 A CA 002472186A CA 2472186 A CA2472186 A CA 2472186A CA 2472186 A1 CA2472186 A1 CA 2472186A1
Authority
CA
Canada
Prior art keywords
dose
administered
total weekly
weekly dose
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002472186A
Other languages
English (en)
French (fr)
Inventor
Maurice J. Wolin
Sandra Milan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2472186A1 publication Critical patent/CA2472186A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002472186A 2002-01-18 2003-01-18 Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein Abandoned CA2472186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34915802P 2002-01-18 2002-01-18
US60/349,158 2002-01-18
PCT/US2003/001394 WO2003061571A2 (en) 2002-01-18 2003-01-18 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein

Publications (1)

Publication Number Publication Date
CA2472186A1 true CA2472186A1 (en) 2003-07-31

Family

ID=27613252

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002472186A Abandoned CA2472186A1 (en) 2002-01-18 2003-01-18 Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein

Country Status (6)

Country Link
US (1) US20030235556A1 (https=)
EP (1) EP1569689A4 (https=)
JP (1) JP2005525317A (https=)
AU (1) AU2003210549A1 (https=)
CA (1) CA2472186A1 (https=)
WO (1) WO2003061571A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
CN102159236A (zh) 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein

Also Published As

Publication number Publication date
WO2003061571A3 (en) 2005-07-07
JP2005525317A (ja) 2005-08-25
WO2003061571A2 (en) 2003-07-31
AU2003210549A1 (en) 2003-09-02
AU2003210549A8 (en) 2005-11-17
EP1569689A4 (en) 2009-08-05
EP1569689A2 (en) 2005-09-07
US20030235556A1 (en) 2003-12-25

Similar Documents

Publication Publication Date Title
US7306801B2 (en) Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
US20030185796A1 (en) Methods of therapy for non-hodgkin's lymphoma
US20020009427A1 (en) Methods of therapy for non-hodgkin's lymphoma
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
EP1532174B3 (en) Anti-igf-i receptor antibody
AU2009201236B2 (en) Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
CA2469045A1 (en) Methods of therapy for non-hodgkin's lymphoma
JP7448552B2 (ja) がんの併用療法
US20250059247A1 (en) Interleukin 21 variants
US20060251617A1 (en) Methods for treating lymphomas
US20030235556A1 (en) Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
KR20220140534A (ko) 암 치료를 위한 egfr 억제제와 ror1 억제제의 조합
US20070274948A1 (en) Methods of Therapy for Chronic Lymphocytic Leukemia
EP1935431A2 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US11773160B1 (en) Immune-stimulating IL-2 fusion proteins
US20240156974A1 (en) Compositions and methods for modulation of antibody activity
HK1156231A (en) Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued